1-20 of 30
protein p53
Close
Sort by
Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Clinical Trials & Observations
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2438–2446.
https://doi.org/10.1182/bloodadvances.2020003895
Published: 2021
Includes: Supplemental data
Journal Articles

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma

Stephan R. Bohl, Laura K. Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik, Martin Szyska, Tamara J. Blätte, Sarah Knödler, Linda Röhner, Denise Miller, Miriam Kull, Christian Langer, Hartmut Döhner, Anthony Letai, Frederik Damm, Dirk Heckl, Lars Bullinger, Jan Krönke
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2391–2402.
https://doi.org/10.1182/bloodadvances.2020003541
Published: 2021
Includes: Supplemental data
Journal Articles

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

Elina Parri, Heikki Kuusanmäki, Daria Bulanova, Satu Mustjoki, Krister Wennerberg
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1862–1875.
https://doi.org/10.1182/bloodadvances.2020003300
Published: 2021
Includes: Supplemental data
Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Clinical Trials & Observations
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1552–1564.
https://doi.org/10.1182/bloodadvances.2020003734
Published: 2021
Includes: Supplemental data
Journal Articles

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Clinical Trials & Observations
Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Jean-Christophe Ianotto, Brigitte Dupriez, Françoise Boyer, Maxime Renard, Olivier Mansier, Anne Murati, Jérôme Rey, Gabriel Etienne, Véronique Mansat-De Mas, Suzanne Tavitian, Olivier Nibourel, Stéphane Girault, Yannick Le Bris, François Girodon, Dana Ranta, Jean-Claude Chomel, Pascale Cony-Makhoul, Pierre Sujobert, Margot Robles, Raouf Ben Abdelali, Olivier Kosmider, Laurane Cottin, Lydia Roy, Ivan Sloma, Fabienne Vacheret, Mathieu Wemeau, Pascal Mossuz, Borhane Slama, Vincent Cussac, Guillaume Denis, Anouk Walter-Petrich, Barbara Burroni, Nathalie Jézéquel, Stéphane Giraudier, Eric Lippert, Gérard Socié, Jean-Jacques Kiladjian, Valérie Ugo
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1442–1451.
https://doi.org/10.1182/bloodadvances.2020003444
Published: 2021
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Clinical Trials & Observations
Pierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, Barbara Mora, Emmanuelle Verger, Nabih Maslah, Aurelie Plessier, Pierre-Emmanuel Rautou, Isabelle Ollivier-Hourman, Victor De Ledinghen, Odile Goria, Christophe Bureau, Claudia Siracusa, Dominique Valla, Stephane Giraudier, Francesco Passamonti, Jean-Jacques Kiladjian
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3708–3715.
https://doi.org/10.1182/bloodadvances.2020002414
Published: 2020
Includes: Supplemental data
Journal Articles

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Clinical Trials & Observations
Preetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, Chi Young Ok, Krystle Nomie, Graciela Nogueras Gonzalez, Omarya Gonzalez-Pagan, Holly A. Hill, Hun Ju Lee, Luis Fayad, Jason Westin, Loretta Nastoupil, Frederick Hagemeister, Wendy Chen, Onyeka Oriabure, Maria Badillo, Changying Jiang, Yao Yixin, Shaoying Li, Guilin Tang, C. Cameron Yin, Keyur P. Patel, Leonard Jeffrey Medeiros, Ranjit Nair, Sairah Ahmed, Swaminathan P. Iyer, Selvi Thirumurthi, Richard Champlin, Guofan Xu, Pan Tinsu, David Santos, Ruiping Wang, Guangchun Han, Jianhua Zhang, Xingzhi Song, Sattva Neelapu, Jorge Romaguera, Andy Futreal, Christopher Flowers, Nathan Fowler, Linghua Wang, Michael L. Wang
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1038–1050.
https://doi.org/10.1182/bloodadvances.2019001396
Published: 2020
Includes: Supplemental data
Journal Articles

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Bachisio Ziccheddu, Giulia Biancon, Filippo Bagnoli, Chiara De Philippis, Francesco Maura, Even H. Rustad, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, Efstathios Kastritis, Meletios A. Dimopoulos, Michele Cavo, Cristiana Carniti, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli
Journal: Blood Advances
Blood Adv (2020) 4 (5): 830–844.
https://doi.org/10.1182/bloodadvances.2019000779
Published: 2020
Includes: Supplemental data
Journal Articles

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Clinical Trials & Observations
Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Chia-Lang Hsu, Hsin-An Hou, Cheng-Hong Tsai, Wen-Chien Chou, Hwei-Fang Tien
Journal: Blood Advances
Blood Adv (2020) 4 (4): 644–654.
https://doi.org/10.1182/bloodadvances.2019001185
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Clinical Trials & Observations
Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Blood Advances
Blood Adv (2020) 4 (4): 599–606.
https://doi.org/10.1182/bloodadvances.2019000795
Published: 2020
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data
Journal Articles

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

Clinical Trials & Observations
Ashwin Sridharan, Carolina D. Schinke, George Georgiev, Mariana Da Silva Ferreira, Victor Thiruthuvanathan, Ian MacArthur, Tushar D. Bhagat, Gaurav S. Choudhary, Srinivas Aluri, Jiahao Chen, Kith Pradhan, Yu Xia, Maya Panjikaran, Gregory Sims, Chirag K. Bhagat, Ryan Bender, Lauryn Keeler, Armin Graber, Christoph Heuck, Frederick A. Fletcher, Daisy Alapat, Niels Weinhold, Sarah K. Johnson, Amittha Wickrema, Bart Barlogie, Gareth J. Morgan, Aditi Shastri, Ulrich Steidl, Britta Will, Amit Verma
Journal: Blood Advances
Blood Adv (2019) 3 (23): 3962–3967.
https://doi.org/10.1182/bloodadvances.2019000731
Published: 2019
Includes: Supplemental data
Journal Articles

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

Brian Reilly, Tiffany N. Tanaka, Dinh Diep, Huwate Yeerna, Pablo Tamayo, Kun Zhang, Rafael Bejar
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2845–2858.
https://doi.org/10.1182/bloodadvances.2019000192
Published: 2019
Includes: Supplemental data
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019
Journal Articles

Germline deletion of ETV6 in familial acute lymphoblastic leukemia

Evadnie Rampersaud, David S. Ziegler, Ilaria Iacobucci, Debbie Payne-Turner, Michelle L. Churchman, Kasmintan A. Schrader, Vijai Joseph, Kenneth Offit, Katherine Tucker, Rosemary Sutton, Meera Warby, Georgia Chenevix-Trench, David G. Huntsman, Maria Tsoli, R. Scott Mead, Chunxu Qu, Vasiliki Leventaki, Gang Wu, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1039–1046.
https://doi.org/10.1182/bloodadvances.2018030635
Published: 2019
Journal Articles

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition

Céline Moison, Vincent-Philippe Lavallée, Clarisse Thiollier, Bernhard Lehnertz, Isabel Boivin, Nadine Mayotte, Yves Gareau, Mélanie Fréchette, Valérie Blouin-Chagnon, Sophie Corneau, Sylvie Lavallée, Sébastien Lemieux, Anne Marinier, Josée Hébert, Guy Sauvageau
Journal: Blood Advances
Blood Adv (2019) 3 (4): 552–563.
https://doi.org/10.1182/bloodadvances.2018028480
Published: 2019
Includes: Supplemental data
Journal Articles

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

Clinical Trials & Observations
Bridget K. Marcellino, Ronald Hoffman, Joseph Tripodi, Min Lu, Heidi Kosiorek, John Mascarenhas, Raajit K. Rampal, Amylou Dueck, Vesna Najfeld
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3581–3589.
https://doi.org/10.1182/bloodadvances.2018024018
Published: 2018
Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3070–3080.
https://doi.org/10.1182/bloodadvances.2018020206
Published: 2018